Journal of Clinical Hypertension · 2022 · 29 citations · 26 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyDrug DesignBlood Pressure ControlBlood Pressure ManagementCardiovascular PharmacologyHypertension ControlHypertension ManagementHypertension PharmacotherapyAntihypertensive Drug TherapyAntihypertensive TreatmentBlood PressureEndothelin Receptor AntagonistsPrecisionRandomized Clinical TrialsRandomized Controlled Trial BaselineTreatment-resistant Hypertension
The design and baseline data of the PRECISION study, which evaluates the effect of the dual endothelin receptor antagonist aprocitentan on blood pressure (BP) in patients with resistant hypertension (RHT) are presented. The study is a blinded, randomized, parallel-group Phase 3 study and its three-part design assesses the short-term and sustained long-term effects of aprocitentan on BP. Results are expected in 2022. Patients with uncontrolled BP (measured as unattended automated office BP) despite the use of three or more antihypertensive medications for at least 1 year were screened. They were switched to a single-tablet triple fixed combination antihypertensive therapy for at least 4 weeks before entering a single-blind placebo run-in period. The 4-week placebo run-in period further excluded placebo responders. The randomization period consisted of three sequential parts: (1) a 4-week double-blind part with aprocitentan 12.5 mg, 25 mg, or placebo (1:1:1 ratio); (2) a 32-week single-blind part with aprocitentan 25 mg; and (3) a 12-week randomized withdrawal part with aprocitentan 25 mg or placebo (1:1 ratio). The purpose was to demonstrate the BP lowering effect of aprocitentan in RHT (Part 1) and the persistence of this effect (Parts 2 and 3). Out of 1965 screened patients, 730 were randomized resulting in an overall inclusion failure rate of 62.8%. The most common reason for exclusion (44.4% of all screened patients) was failure to meet the BP inclusion criteria. These results underline the high proportion of pseudoresistant hypertension among patients referred for RHT.
26
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams, Giuseppe Mancia, Wilko Spiering et al. · European Heart Journal · 2018 · 10.4K citations · Full text
Bin Zhou, Rodrigo M. Carrillo‐Larco, Goodarz Danaei et al. · The Lancet · 2021 · 3.7K citations · Full text
Medicine, Chronic Disease Control, Clinical Epidemiology +16
A Controlled Trial of Renal Denervation for Resistant Hypertension
Deepak L. Bhatt, David E. Kandzari, William W. O’Neill et al. · New England Journal of Medicine · 2014 · 2.2K citations
Bryan Williams, Thomas M. MacDonald, S. V. Morant et al. · The Lancet · 2015 · 1.2K citations · Full text
Pharmacy, Pharmacotherapy, Cardiovascular Pharmacotherapy +16
Effects of Treatment on Morbidity in Hypertension
JAMA · 1967 · 1.1K citations
Medicine, Neurology, Psychiatry +8